Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2026)

Barinthus Biotherapeutics has reported Common Equity for 7 years, with the latest figure at $66.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 42.56% year-over-year to $66.4 million; the trailing twelve-month figure through Mar 2026 stood at $66.4 million (down 42.56% YoY), and the FY2025 full-year result was $74.3 million, down 42.91% from the prior year.
• Common Equity for Q1 2026 stood at $66.4 million, down from $74.3 million in the prior quarter.
• The five-year high for Common Equity was $254.8 million in Q2 2022, with the low at $66.4 million in Q1 2026.
• Historically, Common Equity has averaged $170.0 million across 5 years, with a median of $172.0 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 579.14% — and 2025, when it tumbled 46.97%.
• Barinthus Biotherapeutics' Common Equity stood at $243.2 million in 2022, then decreased by 23.11% to $187.0 million in 2023, then plunged by 30.41% to $130.1 million in 2024, then slumped by 42.91% to $74.3 million in 2025, then slipped by 10.62% to $66.4 million in 2026.
• The last three Common Equity figures came in at $66.4 million (Q1 2026), $74.3 million (Q4 2025), and $84.6 million (Q3 2025), per Business Quant data.